Lilly-partnered radiopharma startup Aktis Oncology raises $175M

Kyle LaHucik

Senior Reporter

As other young radiopharmaceutical companies get acquired by drugmakers, Boston-based Aktis Oncology wants to become one of the field’s next hot startups.

On Monday, it …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Lilly-partnered radiopharma startup Aktis Oncology raises $175M

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

Updated: Roche buys Regor’s CDK inhibitors for $850M upfront amid push to develop 20 ‘transformative’ medicines

Updated: Prime Medicine whittles down pipeline, signs gene editing deal with Bristol Myers

Poseida shares incremental Phase 1 update for Roche-partnered off-the-shelf CAR-T

For some multiple myeloma patients, Carvykti cut risk of death by 45%

The Endpoints 11 winners: Big bets on AI, new frontiers in editing, a neuro renaissance and Chinese chemistry

3 Tiers for AAV Potency Assay Development Success

Lil­ly-part­nered ra­dio­phar­ma start­up Ak­tis On­col­o­gy rais­es $175M

Senior Reporter

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

Lilly-partnered radiopharma startup Aktis Oncology raises $175M